CytomX Therapeutics Quick Ratio 2014-2022 | CTMX
Historical quick ratio values for CytomX Therapeutics (CTMX) over the last 10 years.
| CytomX Therapeutics Quick Ratio Historical Data |
| Date |
Current Assets - Inventory |
Current Liabilities |
Quick Ratio |
| 2022-12-31 |
$0.00B |
$0.15B |
0.00 |
| 2022-09-30 |
$0.00B |
$0.10B |
0.00 |
| 2022-06-30 |
$0.00B |
$0.10B |
0.00 |
| 2022-03-31 |
$0.00B |
$0.10B |
0.00 |
| 2021-12-31 |
$0.00B |
$0.08B |
0.00 |
| 2021-09-30 |
$0.00B |
$0.10B |
0.00 |
| 2021-06-30 |
$0.00B |
$0.09B |
0.00 |
| 2021-03-31 |
$0.00B |
$0.10B |
0.00 |
| 2020-12-31 |
$0.00B |
$0.10B |
0.00 |
| 2020-09-30 |
$0.00B |
$0.10B |
0.00 |
| 2020-06-30 |
$0.00B |
$0.10B |
0.00 |
| 2020-03-31 |
$0.00B |
$0.11B |
0.00 |
| 2019-12-31 |
$0.00B |
$0.09B |
0.00 |
| 2019-09-30 |
$0.00B |
$0.08B |
0.00 |
| 2019-06-30 |
$0.00B |
$0.08B |
0.00 |
| 2019-03-31 |
$0.00B |
$0.10B |
0.00 |
| 2018-12-31 |
$0.00B |
$0.10B |
0.00 |
| 2018-09-30 |
$0.00B |
$0.09B |
0.00 |
| 2018-06-30 |
$0.00B |
$0.08B |
0.00 |
| 2018-03-31 |
$0.00B |
$0.07B |
0.00 |
| 2017-12-31 |
$0.00B |
$0.06B |
0.00 |
| 2017-09-30 |
$0.00B |
$0.07B |
0.00 |
| 2017-06-30 |
$0.00B |
$0.06B |
0.00 |
| 2017-03-31 |
$0.00B |
$0.04B |
0.00 |
| 2016-12-31 |
$0.00B |
$0.04B |
0.00 |
| 2016-09-30 |
$0.00B |
$0.02B |
0.00 |
| 2016-06-30 |
$0.00B |
$0.02B |
0.00 |
| 2016-03-31 |
$0.00B |
$0.02B |
0.00 |
| 2015-12-31 |
$0.00B |
$0.02B |
0.00 |
| 2015-09-30 |
$0.00B |
$0.01B |
0.00 |
| 2015-06-30 |
$0.00B |
|
0.00 |
| 2015-03-31 |
$0.00B |
|
0.00 |
| 2014-12-31 |
$0.00B |
|
0.00 |
| 2014-09-30 |
$0.00B |
|
0.00 |
| 2013-12-31 |
$0.00B |
$0.00B |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.118B |
$0.053B |
|
CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered in South San Francisco, California.
|
